1,610 cases of Carboxymethylcellulose Sodium Ophthalmic Gel 1%; national drug code (NDC): 50268-066-15 13,872 cases of Artificial Tears Ophthalmic Solution; national drug code (NDC): 50268-043-15 ...

13,872 cases of Artificial Tears Ophthalmic Solution ; Each of these products is identified by its national drug code (NDC), available on the FDA’s recall website and AvKARE’s press release.

NDC #50268-678-15 Polyvinyl Alcohol Ophthalmic Solution; The recalled products were shipped out May 2023 through April 2025, and have expiration dates ranging from April 2025 through March 2027.

14,333 cases of polyvinyl alcohol ophthalmic solution (NDC 50268-678-15). The recalled products were shipped between May 26, 2023, and April 21, 2025, and should no longer be used.

The FDA has approved Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride 0.7%; Alcon) ophthalmic solution, formerly prescribed as Pazeo®, for sale over-the-counter.

Key takeaways: Phentolamine ophthalmic solution 0.75% will be evaluated in 545 participants with presbyopia. Topline data are expected in 2025. Ocuphire Pharma has dosed the first participants in ...

Amring is offering timolol maleate ophthalmic solution, 0.5%, 60 pack of 0.3 ml unit dose vials, which is a generic of Timoptic in Ocudose.

The FDA said Apotex didn’t issue a press release on May 28 when it made the actual recalls of the following products. Azelastine HCl Ophthalmic Solution, USP, 0.05%, 6 mL, 105,456 bottles from ...

Phentolamine Ophthalmic Solution 0.75% has the potential to be the first treatment for keratorefractive patients suffering from these debilitating symptoms.” Story Continues Presentation details ...

Glenmark Gets FDA Approval For Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) March 20, 2025 — 11:58 pm EDT Written by RTTNews.com for RTTNews -> ...

On May 18 th, 2023, U.S. Food and Drug Administration (FDA) approved MIEBO™ (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) followed by the approval of VEVYE™ (cyclosporine ...